Linked infacebooktwitteryoutube
Illumina

Illumina Launches Pilot Proteomics Program with UK Biobank and Industry Partners

Naveris

NavDx Test Expands Availability for Enhanced Surveillance in HPV+ Anal Cancer Patients

QIAGEN

QIAGEN Enhances QIAcuity Digital PCR with Expanded Multiplexing Capabilities

Boehringer Ingelheim

Boehringer Ingelheim Licenses Synaffix’s ADC Technology to Advance Cancer Therapies

AIG Hospitals

AIG Hospitals to Launch ₹800 Crore Oncology Centre with South-East Asia’s First Dynamic ARC Proton Therapy

Qiagen

Qiagen Secures FDA Clearance for QIAstat-Dx Gastrointestinal Panel

Ovation.io

Ovation.io Launches Groundbreaking GLP-1 Research Dataset to Advance Precision Medicine

Kotak

Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

Biotechnology

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex Pharmaceuticals

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

Dizal

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

NextEdge Admin
23 Dec 2024
2 min 48 sec
0
Illumina,Bio Big Data Project,Population genomic

Macrogen, a global precision medicine leader, and Illumina Inc. , a global DNA sequencing pioneer, announced their collaboration in supporting Korea’s National Bio Big Data Project. This initiative will sequence and analyze 145,952 Korean genomes, building on a pilot phase since 2020, during which 20,000 genomes, including 10,000 from individuals with rare diseases, were studied. The project aims to establish a genomic reference for 770,000 Koreans by 2028 and one million by 2032, advancing precision medicine as standard care.

“Participating in this transformative project underscores our commitment to enhancing public health in Korea,” said Changhoon Kim, CEO of Macrogen. The project collects and analyzes genomic, clinical, and life-record data from the population, paving the way for precision medicine tailored to Koreans.

Robert McBride, General Manager of Illumina Korea, highlighted the significance of the initiative: “Illumina is honored to contribute to this landmark project, leveraging our global expertise from other population genomics programs to benefit Korea's healthcare ecosystem.”

Population genomic studies worldwide, including in the UK, Japan, and Qatar, are expanding rapidly. However, global datasets predominantly represent European populations, limiting their applicability to diverse groups. “This inequity highlights the critical need for genomic research focused on other populations,” McBride emphasized.

Genomic variation between populations can significantly influence disease susceptibility and treatment responses. Projects like Korea's enhance healthcare equity by providing population-specific insights, improving drug development, and optimizing treatments.

Integrating genomics with advanced technologies like AI and machine learning enables better care, economic growth, and reduced healthcare costs. “Precision medicine benefits everyone—from patients to pharmaceutical companies and governments—by tailoring treatments, reducing development costs, and fostering healthier populations,” added Kim.

This collaboration represents a pivotal step toward realizing the transformative potential of precision medicine.